RNAi researcher Anastasia Khvorova has joined the RNA Therapeutics Institute at the University of Massachusetts Medical School as a professor of molecular medicine.
She most recently served as CSO of RNAi drug developer RXi Pharmaceuticals, and before that was CSO of reagent firm Dharmacon, which was acquired by Thermo Fisher Scientific.